FDA Approves X4 Pharmaceuticals' Xolremdi (Mavorixafor) Capsules For Use In Patients 12 Years Of Age And Older With WHIM Syndrome To Increase The Number Of Circulating Mature Neutrophils And Lymphocytes

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!